arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Emergent BioSolutions Inc.

EBS
$6.64 ▼ -0.11 (-1.63%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
68 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
65
Health
Fair
Bearish
auto_awesome

Analytical Summary

Emergent BioSolutions Inc. faces fundamental challenges with weakness in Debt to Equity. The fundamentals warrant careful consideration of downside risks.

Market Cap $342.6M
Dividend Yield
Revenue Growth 66.3%
Op. Margin -53.4%
ROIC -14.6%
FCF / Share $1.05
Trailing P/E
Price / Book 1.0x
FCF Yield 15.8%
Debt / Equity 1.73
info Valuation on last close. End-of-day price, Sep 23, 2026.

68-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$234.30M
↑ +66.3%
Net Income Profit after all expenses
$6.80M
↓ -90.0%
Operating Margin Operating profit as % of sales
-53.4%
↓ -893.8% 64th
FCF / Share Free cash flow per share
$1.05
↑ +250.0%
Long-Term Debt Long-term obligations
$589.70M
— 0.0%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Debt to EquityDebt to Equity is concerning (bottom quartile)

Health Breakdown

Profitability
68
Returns
68
Financial Health
43
Cash Quality
91

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 18 years · 68 quarters